Seeber Andreas, Gastl Guenther, Ensinger Christian, Spizzo Gilbert, Willenbacher Wolfgang, Kocher Florian, Leitner Christoph, Willenbacher Ella, Amann Arno, Steiner Normann, Eisterer Wolfgang, Voss Andreas, Russell Kenneth, Zwierzina Heinz
Department of Haematoloy and Oncology, Innsbruck Medical University, Austria; Laboratory for Experimental Oncogenomics, Tyrolean Cancer Research Institute, Austria.
Department of Haematoloy and Oncology, Innsbruck Medical University, Austria.
Genes Cancer. 2016 Sep;7(9-10):301-308. doi: 10.18632/genesandcancer.121.
Patients with refractory metastatic cancer have been shown to benefit from molecular profiling of tumor tissue. The ONCO-T-PROFILE project was launched in March 2014 at the Innsbruck Medical University. Within 2 years our project aims to recruit 110 patients with stage IV cancer refractory to standard therapy. Our data presented here are based on an interim-analysis.
Tumor tissue specimens were submitted for molecular profiling to the certified laboratory (Caris Life Science, USA). Druggable tumor targets were selected based on biomarker status to agents with potential clinical benefit. Clinical benefit was defined as a PFS ratio (=PFS upon treatment according to the molecular profile/ PFS upon the last prior therapy) ≥ 1.3.
As of April 2015, tumors from 50 patients have been molecularly profiled and one or more targets were detectable in 48 specimens (98%). So far, 19 (38%) patients have been treated according to their molecular tumor profile. To date, 8 (42%) patients have reached a PFS ratio of ≥ 1.3.
We could show that molecular profiling is feasible in the clinical routine. A proportion of patients might benefit from an individualized treatment approach based on molecular profiling. As a result, we will proceed to enroll patients in ONCO-T-PROFILE.
已证明难治性转移性癌症患者可从肿瘤组织的分子谱分析中获益。ONCO-T-PROFILE项目于2014年3月在因斯布鲁克医科大学启动。我们的项目旨在在两年内招募110例对标准治疗难治的IV期癌症患者。我们在此展示的数据基于一项中期分析。
将肿瘤组织标本送交认证实验室（美国卡里生命科学公司）进行分子谱分析。根据生物标志物状态选择对具有潜在临床益处的药物敏感的肿瘤靶点。临床获益定义为无进展生存期比值（=根据分子谱治疗后的无进展生存期/上次先前治疗后的无进展生存期）≥1.3。
截至2015年4月，已对50例患者的肿瘤进行了分子谱分析，48份标本（98%）中可检测到一个或多个靶点。到目前为止，19例（38%）患者已根据其分子肿瘤谱接受治疗。迄今为止，8例（42%）患者的无进展生存期比值≥1.3。
我们可以证明分子谱分析在临床常规中是可行的。一部分患者可能受益于基于分子谱分析的个体化治疗方法。因此，我们将继续在ONCO-T-PROFILE项目中招募患者。
